Shares of NeuroDerm Ltd. (NASDAQ:NDRM) have received an average recommendation of “Buy” from the seven brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $45.80.

A number of equities research analysts recently commented on NDRM shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $42.00 price target on shares of NeuroDerm in a report on Friday, March 24th. Roth Capital set a $33.00 price target on shares of NeuroDerm and gave the stock a “buy” rating in a report on Thursday, March 2nd. CIBC reaffirmed a “market perform” rating on shares of NeuroDerm in a report on Tuesday, March 7th. Cowen and Company lifted their price target on shares of NeuroDerm from $38.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, March 1st. Finally, Oppenheimer Holdings, Inc. reaffirmed a “market perform” rating on shares of NeuroDerm in a report on Tuesday, March 7th.

NeuroDerm (NASDAQ NDRM) remained flat at $29.45 during mid-day trading on Tuesday. 44,409 shares of the company were exchanged. The company’s market capitalization is $775.65 million. NeuroDerm has a 12-month low of $15.12 and a 12-month high of $30.75. The firm has a 50-day moving average of $24.39 and a 200 day moving average of $24.31.

NeuroDerm (NASDAQ:NDRM) last posted its earnings results on Thursday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.13. Analysts expect that NeuroDerm will post ($2.02) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/06/20/neuroderm-ltd-ndrm-receives-consensus-recommendation-of-buy-from-analysts.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. acquired a new position in NeuroDerm during the first quarter worth $223,000. Nationwide Fund Advisors acquired a new position in NeuroDerm during the first quarter worth $226,000. HighTower Advisors LLC acquired a new position in NeuroDerm during the first quarter worth $242,000. NJ State Employees Deferred Compensation Plan acquired a new position in NeuroDerm during the first quarter worth $266,000. Finally, Tudor Investment Corp Et Al acquired a new position in NeuroDerm during the fourth quarter worth $222,000. Institutional investors and hedge funds own 50.24% of the company’s stock.

NeuroDerm Company Profile

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.